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Abstract  The  molecular  basis  of  ﬂuconazole  resistance  in  Cryptococcus  neoformans  has  been
poorly studied.  A  common  azole  resistance  mechanism  in  Candida  species  is  the  acquisition  of
point mutations  in  the  ERG11  gene  encoding  the  enzyme  lanosterol  14--demethylase,  target
of the  azole  class  of  drugs.  In  C.  neoformans  only  two  mutations  were  described  in  this  gene.
In order  to  evaluate  other  mutations  that  could  be  implicated  in  ﬂuconazole  resistance  in  C.
neoformans  we  studied  the  genomic  sequence  of  the  ERG11  gene  in  11  clinical  isolates  with
minimal inhibitory  concentration  (MIC)  values  to  ﬂuconazole  of  ≥16  g/ml.  The  sequencing
revealed  the  G1855A  mutation  in  3  isolates,  resulting  in  the  enzyme  amino  acid  substitution
G484S. These  strains  were  isolated  from  two  ﬂuconazole-treated  patients.  This  mutation  would
not intervene  in  the  susceptibility  to  itraconazole  and  voriconazole.
© 2016  Asociacio´n  Argentina  de  Microbiolog´ıa.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
PALABRAS  CLAVE
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Sustitución  aminoacídica  en  la  enzima  lanosterol  14  -demetilasa  de  Cryptococcus
neoformans  involucrada  en  la  resistencia  al  ﬂuconazol  de  aislamientos  clínicosResistencia  al
ﬂuconazol;
Resumen  Las  bases  moleculares  de  la  resistencia  al  ﬂuconazol  en  Cryptococcus  neoformans
han sido  poco  estudiadas.  Un  mecanismo  de  resistencia  a  los  azoles  en  Candida  albicans  es
es  puntuales  en  el  gen  ERG11,  que  codiﬁca  la  enzima  lanosterol  14
s  drogas  azólicas.  En  C.  neoformans  solo  2  mutaciones  en  este  gen
objetivo  de  estudiar  otras  mutaciones  que  podrían  estar  implicadasGen  ERG11;
Sustitución
aminoacídica;
la adquisición  de  mutacion
-demetilasa,  blanco  de  la
han sido  descriptas.  Con  el  Mutación en la  resistencia  al  ﬂuconazol  en  C.  neoformans,  realizamos  la  secuenciación  del  gen  ERG11
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de  11  aislamientos  clínicos  con  valores  de  concentración  inhibitoria  mínima  (CIM)  de  ﬂuconazol
≥16 g/ml.  En  3  aislamientos,  la  secuenciación  reveló  la  mutación  G1855A,  que  da  como  resul-
tado la  sustitución  aminoacídica  G484S.  Estos  aislamientos  fueron  recuperados  de  2  pacientes
tratados  con  ﬂuconazol.  Esta  mutación  no  intervendría  en  la  sensibilidad  al  itraconazol  y  al
voriconazol.
© 2016  Asociacio´n  Argentina  de  Microbiolog´ıa.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/s/by-nc-nd/
4.0/).
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aCryptococcosis  is  a  life-threatening  infection  caused
y  the  encapsulated  basidiomycetous  yeast  Cryptococcus
eoformans  that  affects  mainly  immunocompromised
atients,  especially  those  suffering  from  AIDS4.  The  most
ommon  manifestation  is  cryptococcal  meningitis,  which
s  fatal  unless  treated.  C.  neoformans  is  found  worldwide
nd  is  responsible  for  approximately  one  million  cases/year
hich  result  in  over  600  000  deaths  annually7.
Fluconazole  (FLC),  a  triazole  antifungal  drug,  is  the  drug
f  choice  for  consolidation  and  maintenance  therapy  due
o  its  efﬁcacy,  excellent  central  nervous  system  penetration
nd  minor  toxic  effects9.
Due  to  the  use  of  FLC  in  long-term  therapies,  there  is
oncern  about  the  emergence  of  antifungal  resistance  in
.  neoformans3.  Several  authors  have  associated  in  vitro
esistance  with  treatment  failure  and  infection  relapse1,3.
The  molecular  basis  of  resistance  to  azole  antifungals  has
een  poorly  studied  in  C.  neoformans.
One  resistance  mechanism  proposed  is  the  duplication
f  chromosome  1  and  consequently  of  two  of  its  resident
enes:  ERG11, which  encodes  for  the  FLC  target  enzyme
anosterol  14--demethylase,  and  AFR1, which  encodes  for
n  ABC  transporter14.  It  has  been  demonstrated  that  upre-
ulation  of  the  AFR1  gene  is  involved  in  the  resistance  to
LC  in  this  yeast11.
A  common  FLC  resistance  mechanism  in  Candida  species
s  the  acquisition  of  point  mutations  in  the  ERG11  gene
esulting  in  an  altered  target  with  reduced  afﬁnity  for
r  inability  to  bind  azoles8.  Only  two  mutations  in  this
ene  have  been  associated  with  resistance  to  FLC  in  C.
eoformans10,13.  Furthermore,  one  of  them  caused  resis-
ance  to  both  FLC  and  voriconazole  (VRC)  and  increased
usceptibility  to  itraconazole  (ITC)  and  posaconazole  (PSC);
his  mutation  was  identiﬁed  in  an  isolate  with  an  exception-
lly  high  level  of  heteroresistance13.
To  elucidate  if  more  mutations  could  be  implicated  in
LC  resistance,  we  studied  the  ERG11  genomic  sequence
f  eleven  clinical  isolates  from  the  Mycology  Department
ulture  Collection  (DMic)  of  Instituto  Nacional  de  Enfer-
edades  Infecciosas  ‘‘Dr.  Carlos  G.  Malbrán’’,  Buenos  Aires,
rgentina.  The  research  proposal  does  not  involve  experi-
entation  on  humans  and  non-clinical  samples  were  used.
ncluding  yeast  isolates  are  anonymous  and  belong  to  the
ycology  Department  Culture  Collection.  These  isolates
ere  selected  for  having  high  minimal  inhibitory  concentra-
ion  (MIC)  values  to  FLC  (MIC  values  ≥16  g/ml).  One  isolate
ith  a  lower  MIC  value  was  incorporated  because  it  came
rom  a  patient  who  had  presented  an  isolate  with  a  high
IC  value.  The  isolates  and  the  patients’  clinical  data  are
escribed  in  Table  1.  All  the  isolates  included  in  this  study
T
p
gere  C.  neoformans  var  grubii  genotype  VNI  determined  by
CR-RFLP  of  the  URA5  gene6.
The  minimal  inhibitory  concentration  (MIC)  was  deter-
ined  according  to  the  European  Committee  on  Antimi-
robial  Susceptibility  Testing  (EUCAST)  E.Def  7.2  reference
ocument2.  Amphotericin  B  (AMB)  and  ITC  (Sigma--Aldrich
uimica,  Argentina);  FLC  and  VRC  (Pﬁzer  S.A.,  Argentina);
ere  the  drugs  tested  and  were  provided  as  standard
owders  of  known  potency.  The  susceptibility  tests  were
epeated  from  4  to  10  times  for  each  isolate.
DNA  was  extracted  according  to  the  method  reported
y  Möller  et  al.  To  obtain  the  complete  sequence  of  the
RG11  gene,  four  PCRs  were  performed  according  to  Rodero
t  al.10. PCR  products  were  puriﬁed  using  the  PureLink  puriﬁ-
ation  kit  (Invitrogen)  and  were  sequenced  on  both  strands
sing  the  initial  ampliﬁcation  primers  with  an  automated
NA  sequencer  ABI  Genetic  Analyzer  3500  (Applied  Biosys-
ems,  CA).  Sequences  were  edited  using  the  BioEdit  Versión
.0.0  (Tom  May,  North  Carolina  State  University).  All  ERG11
ene  sequences  were  deposited  in  the  GenBank  database
Table  2).
The  FLC  susceptibility  testing  conﬁrmed  that  the
trains  selected  for  this  study  presented  high  MIC  values
≥16  g/ml)  (Table  2).  All  the  isolates  exhibited  similar
n  vitro  susceptibility  patterns  toward  AMB,  ITC  and  VRC  as
he  FLC  susceptible  isolate  included  in  this  study  and  other
solates  of  our  collection  with  FLC  MIC  values  <16  g/ml
data  not  shown).  Only  one  isolate  (patient  B,  isolate  no.
Mic  021206)  exhibited  higher  MIC  values  to  ITC  and  VRC
0.5  and  1  g/ml  respectively).
The  Genbank  accession  numbers  of  the  ERG11  gene
equences  obtained  are  listed  in  Table  2. Eight  of  the  eleven
solates  studied  contained  nucleotide  variations  compared
o  the  wild  type  published  sequences  of  ERG11  (GenBank
ccession  No.  AY265353  and  JQ044790).  Only  one  of  these
ucleotide  variations  resulted  in  an  amino  acid  substitu-
ion,  the  G1855A  mutation  producing  substitution  G484S.
wo  isolates  recovered  from  the  same  episode  of  patient
 and  the  isolate  recovered  from  the  third  episode  of
atient  A  presented  this  mutation.  We  include  in  this
tudy  an  isolate  recovered  from  the  initial  episode  of
atient  A,  which  did  not  contain  this  nucleotide  varia-
ion  and  was  susceptible  to  FLC.  The  other  ﬁve  isolates,
btained  from  three  patients,  contained  different  combi-
ations  of  ﬁve  nucleotide  variations  that  did  not  result  in
ny  amino  acid  substitution:  C233T  present  in  an  intron,
nd  the  silent  nucleotide  changes  A1032G,  C1659T,  A1779G.
hree  isolates  did  not  exhibit  nucleotide  variation  com-
ared  to  the  published  wild  type  sequence  of  the  ERG11
ene.
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Table  1  Medical  records  and  clinical  source  of  the  Isolates
Patient  Episode  Isolate  no.  Clinical
source
Clinical  data
A First  episode  DMic  032018  CSF  -  Cryptococcosis  as  hallmark  of  HIV  infection.
- AMB  treatment,  until  a  580  mg  cumulative  dose.
- The  patient  left  the  hospital  without  medical  authorization.
Two months  later  he  was  readmitted  with  a  relapse.a
-  AMB  treatment  was  restarted,  until  a  975  mg  cumulative  dose.
- FLC  treatment  started  (800  mg/day)  with  a  favorable  outcome.
Third  episode DMic  031564 CSF  -  Ten  months  after  the  ﬁrst  episode.
- The  patient  died.
B  Second  episode  DMic  021206  CSF  Unknown
C  DMic  031528  Blood  Unknown
D
First  isolate  DMic  951594  CSF  Both  isolates  were  recovered  from  different  samples  of  the  same
episode.  Prior  to  these  isolates  the  patient  had  received  AMB
(1300 mg  of  cumulative  dose)  and  over  one  month  of  treatment
with FLC  800  mg/day.
Second  Isolate DMic  961930 CSF
E  DMic  042077  CSF  Unknown
F  DMic  073103  Unknown  Unknown
G  DMic  052504  CSF  Unknown
H
Third  episode DMic  031631 CSF a First  episode:  treatment  with  AMB  50  mg/day.
a Second  episode:  4  months  later.  FLC  400  mg/day  for  one  month.
Then FLC  200  mg/day.
Fifth  episode  DMic  021146  CSF  Third  episode:  13  months  after  the  ﬁrst  episode.
a Fourth  episode:  21  months  after  the  ﬁrst  episode.  Treatment
with FLC  1200  mg/day.
Fifth  episode:  34  months  after  the  ﬁrst  episode.
Treatment  with  AMB  three  times  a  week.
Sixth  episode  DMic  031862  CSF  Sixth  episode:  42  months  after  the  ﬁrst  episode.  Treatment  with
AMB 50  mg/day  was  restarted.  After  that,  the  patient  was  treated
for 1½ month  with  posaconazole.  The  patient  left  the  hospital
and was  readmitted  1½ month  later.  The  isolate  from  the  sixth
episode was  recovered  and  the  patient  died.
CSF, cerebrospinal ﬂuid; AMB, amphotericin B; FLC, ﬂuconazole; PSC, Posaconazole.
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The  study  of  speciﬁc  C.  neoformans  physiological
responses  and  the  possible  resistance  mechanisms  to  drugs
used  in  the  treatment  of  cryptococcosis  are  important  both
to  identify  potential  new  treatments  for  the  infection  and
to  enhance  the  inhibitory  effects  of  existing  drugs.
The  ERG11  gene  encodes  the  lanosterol  14--
demethylase  involved  in  ergosterol  biosynthesis  and
the  primary  target  for  the  azole  class  of  antifungals.
Several  point  mutations  in  this  gene  leading  to  different
amino  acid  substitutions  have  been  shown  to  decrease  the
target  afﬁnity  for  FLC  resulting  in  drug  resistance  in  C.
albicans5,8.  Two  of  them  have  been  described  and  related
to  FLC  resistance  in  C.  neoformans: substitutions  G484S
and  Y145F10,13.
In  this  study,  three  clinical  isolates  with  high  MIC  val-
ues  presented  the  G484S  substitution.  These  isolates  were

l
eecovered  from  two  patients  who  had  had  previous  cryp-
ococcosis  episodes  with  a history  of  treatment  with  FLC.
oreover,  we  were  able  to  study  the  isolate  obtained  from
ne  of  these  patients’  ﬁrst  episode,  where  cryptococcosis
as  the  hallmark  of  HIV  and  the  patient  had  not  received  any
reatment.  This  initial  isolate  presented  a  lower  MIC  value
nd  did  not  carry  the  amino  acid  substitution.  These  results
einforce  the  hypothesis  that  relates  the  G484S  substitution
o  FLC  resistance  in  C.  neoformans. This  relationship  was
roposed  previously  by  Rodero  et  al.  as  a  result  of  the  study
f  a  resistant  isolate  recovered  from  a  patient  suffering  four
pisodes  of  relapse10.According  to  the  3-dimensional  model  of  Lanosterol  14-
-demethylase  from  C.  neoformans, the  amino  acid  G484  is
ocated  in  the  heme  environment  into  the  active  site  of  the
nzyme12.  It  is  proposed  that  this  amino  acid  substitution
140
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Table  2  Antifungal  susceptibilities,  nucleotide  mutations  in  the  ERG11  gene  and  amino  acid  substitutions  from  Cryptococcus  neoformans  isolates
Patient Episode Isolate  no. MIC  (g/ml)a Nucleotide
mutationsb
Amino  acid
substitution
Genbank
accession  no.
FLC  ITC  VRC  AMB
A
First  episode  DMic  032018  4  0.13  0.06  0.5  --  --  KP294185
Third  episode  DMic  031564  32  0.03  0.13  0.25  G1855A  G484S  KP334107
B  Second  episode  DMic  021206  64  0.5  1  0.25  --  --  KP419999
C DMic  031528  16  0.03  0.06  0.13  --  --  KP420000
D
First  isolate  DMic  951594  32  <0.015  0.25  0.5  G1855A  G484S  KP420001
Second Isolate  DMic  961930  16  0.06  0.25  0.06  G1855A  G484S  KP420002
E  DMic  042077  16  <0.015  0.25  0.06  C233T  A1032G  A1779G  --  KP635002
F DMic  073103  16  0.03  0.13  0.13  A1032GC1659TA1779G  --  KP635003
G DMic  052504  16  0.03  0.25  0.5  --  --  KP635004
H
Third episode  DMic  031631  16  0.03  0.06  0.25  C233T  A1032G  A1779G  --  KP635005
Fifth episode  DMic  021146  32  0.13  0.5  0.25  C233T  A1032G  A1779G  --  KP635006
Sixth episode  DMic  031862  16  0.13  0.25  0.5  C233T  A1032G  A1779G  --  KP635007
MIC, minimal inhibitory concentration; FLC, ﬂuconazole; ITC, itraconazole; VRC, voriconazole; AMB, amphotericin B.
a The values expressed represent the mode MIC values obtained for each isolate.
b The base numbers are with respect to the ﬁrst ATG codon of the ERG11 gene.
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might  decrease  the  ﬂexibility  required  for  binding  with  the
substrate  and  the  azole  antifungal  agents12.
Mutation  G1885A  leading  to  amino  acid  G484S  substi-
tution  was  found  independently  in  isolates  from  different
patients  and  may  represent  a  ‘‘hot  spot’’  for  the  devel-
opment  of  azole  resistance;  furthermore  this  substitution
correlates  with  substitution  G464S  in  C.  albicans  also  pro-
posed  as  a  ‘‘hot  spot’’  for  that  species8.
The  structure  of  VRC  is  very  similar  to  FLC  and  in  accor-
dance  with  the  three-dimensional  models  in  C.  neoformans,
VRC  might  show  higher  afﬁnity  with  the  enzyme  than  FLC12.
On  the  other  hand  ITC  and  PSC  have  very  long  side  chains
and  might  present  the  lowest  interaction  with  the  enzyme.
With  one  exception,  the  isolates  included  in  the  present
study  exhibited  low  MIC  values  for  VRC  and  ITC;  moreover,
we  found  no  differences  in  the  VRC  and  ITC  MIC  values
between  the  isolates  with  the  G484S  substitution  and  oth-
ers  in  our  collection  susceptible  to  FLC  (data  not  shown),
suggesting  that  the  G484S  substitution  would  not  intervene
in  the  enzyme  interaction  with  ITC  and  VRC.  In  contrast,
the  other  amino  acid  substitution,  the  Y145F,  described  in
C.  neoformans, afforded  resistance  to  VRC  but  increased
susceptibility  to  ITC  and  posaconazole13.
We  also  found  different  combinations  of  ﬁve  nucleotide
variations  that  did  not  result  in  any  amino  acid  substitu-
tion,  which  may  indicate  allelic  differences  present  in  the
ERG11  gene,  and  heterogeneity  in  the  C.  neoformans  pop-
ulation.  These  allelic  differences  were  also  observed  in  C.
albicans  ERG11  gene8.  It  is  worthy  of  note  that  all  the  iso-
lates  included  in  this  study  were  C.  neoformans  var.  grubii
genotype  VNI  in  line  with  the  worldwide  distribution  since
this  genotype  is  the  most  ubiquitous  and  prevalent  and
causes  most  of  the  cryptococcal  infections4,6.
Xu  et  al.  proposed  that  mutation  to  FLC  resistance  in  C.
neoformans  is  a  dynamic  and  heterogeneous  process  involv-
ing  multiple  simultaneous  mechanisms15.  Overexpression  of
efﬂux  transporters  and  chromosome  duplication  may  occur
in  the  isolates  without  any  amino  acid  substitution  and  may
also  be  acting  together  with  the  G484S  amino  acid  sub-
stitution.  It  remains  to  be  determined  how  this  mutation
individually  contributes  to  FLC  resistance.
In  summary,  the  results  showed  that  FCZ  resistance  in
C.  neoformans  may  result  from  the  presence  of  the  G1855A
point  mutation  in  the  ERG11  gene  responsible  for  the  amino
acid  substitution  G484S.  This  mutation  would  not  change
susceptibility  to  ITC  and  VRC.
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